May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Clinical Experience With Biodegradable 3D-Porous Collagen-glycosaminoglycan Scaffold (OculusGenTM) for Treatment of Refractory Glaucoma
Author Affiliations & Notes
  • H.-L. Chen
    Ophthalmology, Chang Gung Memorial Hospital, Taipei, Taiwan
  • X. Li
    Ophthalmology, People's (Renmin) Hospital of Beijing University, Beijing, China
  • F. Yuan
    Ophthalmology, Zhong-Shan Hospital of Fudan University, Shanghai, China
  • W. Hsu
    Ophthalmology, Taipei Medical University Hospital, Taipei, Taiwan
  • Footnotes
    Commercial Relationships H. Chen, OculusGen BIomedical Inc., F; X. Li, OculusGen BIomedical Inc., F; F. Yuan, None; W. Hsu, OculusGen Biomeical Inc., F; Life Spring Bio.Inc., P.
  • Footnotes
    Support OculusGen Biomeical Inc
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 826. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H.-L. Chen, X. Li, F. Yuan, W. Hsu; Clinical Experience With Biodegradable 3D-Porous Collagen-glycosaminoglycan Scaffold (OculusGenTM) for Treatment of Refractory Glaucoma. Invest. Ophthalmol. Vis. Sci. 2007;48(13):826.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: Based on experience learned from earlier animal study, we describe a short-term pilot study that evaluates the safety and efficacy of trabeculectomy with implantation of OculusGen in refractory glaucoma patients. OculusGen, by its characteristics, improves the regenerating tissue-remodeling and reduces scar formation by guiding fibroblast to grow through the matrix pores randomly.

Methods:: In this multi-center, prospective and non-randomized study, 59 patients (M:25, F:34, age: 57.1 ± 12.4 yrs ) underwent trabeculectomy with new device in one eye for refractory glaucoma, which is defined as having previously failed medical, laser or surgical treatment, or some combination thereof. The OculusGen was implanted on the top of the scleral flap at the limbus before closing the conjunctival wound during trabeculectomy operations. Intraocular pressure (IOP), number of medications and complication were assessed before and after surgery.

Results:: The mean preoperative IOP was 38.7 ± 7.5 mmHg with 2.1 ± 0.9 antiglaucoma medications. Postoperatively, the mean IOP at last follow up (9 months) for all eyes was 16.1 ±3.2 mmHg (58.3% reduction, p < 0.05) with 0.3 ±0.2 antiglaucoma medications. There were no significant intra-operative complications in any patients. Post-operative complications including transient shallow anterior chamber, hyphema, choroidal detachment and hypotony, no endophthalmitis occurred in any patients.

Conclusions:: The preliminary results of this study indicate that the OculusGen implantation in trabeculectomy represents a new, safe, simple and effective therapeutic approach for treating refractory glaucoma. Normalization of subconjunctival wound healing by tissue engineering is applied to traditional filtering surgery, bringing a novel approach to anti-scarring. A larger-scale study with a longer follow-up period is required to confirm these observation.The

Clinical Trial:: NCT00320762

Keywords: wound healing • clinical (human) or epidemiologic studies: systems/equipment/techniques • anterior segment 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.